Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience

Ureña, Marina; Brochet, Éric; Lecomte, Milena; Kerneis, Caroline; Carrasco, José Luís; Ghodbane, Walid; Abtan, Jérémie; Alkhoder, Soleiman; Raffoul, Richard; Iung, Bernard; Nataf, Patrick; Vahanian, Alec; Himbert, Dominique

doi:10.1093/eurheartj/ehy271

Cited by 85 publications

(67 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The main mechanism of hemolysis after TMVR is PVL due to incomplete sealing, device undersizing, or progressive left ventricular remodeling (Figure C,D). Cases of severe clinical hemolysis have also been reported following transcatheter mitral valve in valve/ring implantation …”

Section: Incidence and Etiology Of Cardiac Prosthesis‐related Hemolysismentioning

confidence: 99%

See 1 more Smart Citation

Cardiac prostheses‐related hemolytic anemia

Alkhouli

Farooq

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Hemolysis is an unintended sequel of temporary or permanent intracardiac devices. However, limited data exist on the characteristics and treatment of hemolysis in patients with cardiac prostheses. This entity, albeit uncommon, often poses significant diagnostic and management challenges to the clinical cardiologist. In this article, we aim to provide a contemporary overview of the incidence, mechanisms, diagnosis, and management of cardiac prosthesis‐related hemolysis.

show abstract

Section: Incidence and Etiology Of Cardiac Prosthesis‐related Hemolysismentioning

confidence: 99%

“…Cases of severe clinical hemolysis have also been reported following transcatheter mitral valve in valve/ring implantation. 35…”

Section: Hemolysis After Transcatheter Valve Replacementmentioning

confidence: 99%

Cardiac prostheses‐related hemolytic anemia

Alkhouli

Farooq

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…Of 270 potentially relevant articles screened initially, 17 eligible studies including a total of 1017 patients undergoing VIV/VIR‐TMVI were identified (Table ). Only two small‐size study compared VIV‐TMVI with redo MVS, and one of them using a propensity‐score analysis .…”

Section: Resultsmentioning

confidence: 99%

“…Only two small‐size study compared VIV‐TMVI with redo MVS, and one of them using a propensity‐score analysis . Eleven studies analyzed exclusive VIV‐TMVI patients, only one study examined exclusive VIR‐TMVI patients, two studies investigated combined VIV/VIR‐TMVI patients, and three studies researched VIV‐TMVI and VIR‐TMVI patients separately. Deteriorated bioprosthetic valves and failed annuloplasty rings were summarized in Supplementary Table S1, and implanted transcatheter heart valves and approaches in Supplementary Table S2.…”

Section: Resultsmentioning

confidence: 99%

“…Deteriorated bioprosthetic valves and failed annuloplasty rings were summarized in Supplementary Table S1, and implanted transcatheter heart valves and approaches in Supplementary Table S2. The TA approach was exclusively applied in seven studies, the TS approach was exclusively used in two studies and the VIR patients of one study, and both the approaches were utilized in seven studies . In total, the TA and TS approach was used in 40.4% and 55.5% of patients, respectively.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A meta‐analysis of valve‐in‐valve and valve‐in‐ring transcatheter mitral valve implantation

Takagi

Hari

Kawai

et al. 2018

J Interven Cardiology

View full text Add to dashboard Cite

Objectives: We performed a meta-analysis of transcatheter mitral valve implantation (TMVI) for deteriorated bioprosthetic valves (valve-in-valve [VIV]-TMVI) and/or failed annuloplasty rings (valve-in-ring [VIR]-TMVI), comparing observed early (30-day) mortality with predicted operative mortality. Background: It remains unclear whether VIV/VIR-TMVI reduces mortality as compared with redo MVS. Methods: MEDLINE and EMBASE were searched current through 24 July 2018 using Web-based search engines (PubMed and OVID) to identify studies including ≥10 patients undergoing VIV/VIR-TMVI. For each study, data regarding observed 30-day mortality and predicted operative mortality (Society of Thoracic Surgeons Predicted Risk of Mortality [STS-PROM]) were used to generate risk ratios (RRs) and 95% confidence intervals (CIs). Study-specific estimates were combined using the inverse variance-weighted average of logarithmic RRs in the random-effects model. Onegroup meta-analyses of 30-day/late (including 30-day) mortality rates were also performed in the random-effects model.Results: Of 270 potentially relevant articles screened initially, 17 eligible studies including a total of 1017 patients undergoing VIV/VIR-TMVI were identified. In all but four studies, the STS-PROM was available and varied from 7.7% to 22.0% (weighted mean, 11.5%). Pooled analyses of all VIV/VIR-TMVI studies demonstrated the 30-day mortality rate of 5.4% (95%CI, 4.0-6.8%), the midterm (1-to 5-year) mortality rate of 13.7% (95%CI, 9.0-18.5%), and significantly lower observed 30-day mortality than predicted operative mortality (RR, 0.67; 95%CI, 0.49-0.91; P = 0.01).Conclusions: VIV/VIR-TMVI brought about relatively low early and midterm (1-to 5year) mortality, and observed 30-day mortality was significantly lower than predicted operative mortality. K E Y W O R D S meta-analysis, mortality, transcatheter mitral valve implantation, valve-in-ring, valve-in-valve J Interv Cardiol. 2018;31:899-906.wileyonlinelibrary.com/journal/joic

show abstract

Antithrombotic Strategies in Valvular and Structural Heart Disease Interventions

Camaj¹,

Razuk²,

Dangas³

2022

Interventional Cardiology

View full text Add to dashboard Cite

Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience

Abstract: Transcatheter mitral valve implantation using balloon-expandable valves in selected patients with bioprosthesis or annuloplasty failure or severe MAC was associated with a low rate of peri-procedural complications and acceptable long-term outcomes.

Cited by 85 publications

References 28 publications

Cardiac prostheses‐related hemolytic anemia

Cardiac prostheses‐related hemolytic anemia

A meta‐analysis of valve‐in‐valve and valve‐in‐ring transcatheter mitral valve implantation

Antithrombotic Strategies in Valvular and Structural Heart Disease Interventions

Contact Info

Product

Resources

About